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Rotavirus P[4]G2 
in a Vaccinated 
Population, Brazil
To the Editor: Gurgel et al. pro-
vide an early examination of postmar-
keting surveillance data from Brazil, 
one of the fi rst countries to implement 
routine childhood immunization with 
Rotarix vaccine (1). In a community 
with reported vaccination coverage of 
50%, the P[4]G2 strain was detected in 
all 21 rotavirus-positive stool samples 
identifi ed during November 2006–
February 2007. Although monitoring 
effectiveness of Rotarix against P[4]
G2 strains is of interest (2), the small 
sample size, short duration of surveil-
lance, and lack of a comparison group 
preclude fi rm assessment of an asso-
ciation between P[4]G2 predominance 
and vaccination.
Because Rotarix was introduced 
in Brazil in March 2006, most children 
>12 months old (66 [51%] of 129) in 
the study were ineligible for vaccina-
tion. Genotype P[4]G2 was the only 
strain identifi ed even in older children, 
which suggests either a change in dis-
ease ecology from vaccination or the 
random circulation of P[4]G2 strains 
in the community. Ongoing hospital-
based surveillance during 2006 in 3 
regional countries that had not intro-
duced rotavirus vaccine (El Salvador, 
Guatemala, and Honduras) showed 
that P[4]G2 was the predominant cir-
culating strain (prevalence 68%–81%). 
Thus, as previously documented (3,4), 
the predominance of P[4]G2 strains 
after Rotarix introduction in Brazil 
could represent a natural shift unre-
lated to vaccination.
Evaluation of vaccine effective-
ness against specifi c strains will allow 
full assessment of the public health 
impact of vaccination. Although the 
data are sparse in the study from Gur-
gel et al., a comparison of the odds of 
vaccination among rotavirus-positive 
(cases) versus rotavirus-negative 
(controls) children shows 80% vac-
cine effectiveness against P[4]G2 
strains among infants <1 year of age, 
in accordance with recently published 
data from a controlled trial (5). To 
further elucidate vaccine impact, we 
are providing support for vaccine ef-
fectiveness studies in Nicaragua and 
El Salvador and conducting strain 
monitoring before and after licensure 
throughout Latin America.
Manish M. Patel,* 
Lucia Helena de Oliveira,† 
Ana Maria Bispo,† 
Jon Gentsch,* 
and Umesh D. Parashar*
*Centers for Disease Control and Preven-
tion, Atlanta, Georgia, USA; and †Pan 
American Health Organization, Washing-
ton, DC, USA 
References
  1.  Gurgel RQ, Cuevas LE, Vieira SCF, Bar-
ros VCF, Fontes PB, Salustino ET, et al. 
Predominance of rotavirus P[4]G2 in a 
vaccinated population, Brazil. Emerg In-
fect Dis. 2007;13:1571–3.
  2.  Glass RI, Parashar UD, Bresee JS, Tur-
cios R, Fischer TK, Widdowson MA, et 
al. Rotavirus vaccines: current prospects 
and future challenges. Lancet. 2006;368:
323–32.
  3.  Desselberger U, Iturriza-Gomara M, 
Gray JJ. Rotavirus epidemiology and sur-
veillance. Novartis Found Symp. 2001;
238:125–47.
  4.  Santos N, Hoshino Y. Global distribu-
tion of rotavirus serotypes/genotypes and 
its implication for the development and 
implementation of an effective rotavirus 
vaccine. Rev Med Virol. 2005;15:29–56.
  5.  Vesikari T, Karvonen A, Prymula R, 
Schuster V, Tejedor JC, Cohen R, et al. Ef-
fi cacy of human rotavirus vaccine against 
rotavirus gastroenteritis during the fi rst 
2 years of life in European infants: ran-
domised, double-blind controlled study. 
Lancet. 2007;370:1757–63.
Address for correspondence: Manish M. Patel, 
Viral Gastroenteritis Section, Centers for 
Disease Control and Prevention, 1600 Clifton 
Rd NE, Mailstop A47, Atlanta, GA 30333, 
USA; email: aul3@cdc.gov
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 5, May 2008 863 
Letters
Letters commenting on recent articles as 
well as letters reporting cases, outbreaks, 
or original research are welcome. Letters 
commenting on articles should contain no 
more than 300 words and 5 references; they 
are more likely to be published if submit-
ted within 4 weeks of the original article’s 
publication. Letters reporting cases, out-
breaks, or original research should contain 
no more than 800 words and 10 references. 
They may have one Figure or Table and 
should not be divided into sections. All let-
ters should contain material not previously 
published and include a word count.
LETTERS
To the Editor: Gurgel et al. de-
scribed the predominance of P[4]G2 
rotaviruses in a vaccinated population 
in Aracaju, northeastern Brazil (1). 
However, several limitations need to 
be addressed to avoid misinterpreta-
tion of data that could lead to loss of 
confi dence in the vaccine in Brazil and 
other countries.
Brazil was one of the fi rst coun-
tries in Latin America to introduce a 
live, oral, attenuated human rotavirus 
vaccine into a public-sector health 
program. Nevertheless, vaccine cov-
erage levels vary considerably across 
regions (≈40% to >80%) and are 
≈50% in some parts of northern and 
northeastern Brazil. Therefore, draw-
ing conclusions about the vaccine’s 
protection and prevailing rotavirus 
genotypes in a setting where coverage 
is still low seems premature.
Two fi ndings require special con-
sideration. First, although the number 
of patients is small, children <1 year of 
age showed a reduced risk for severe 
rotavirus diarrhea among vaccinated 
(7%) patients compared with nonvac-
cinated (26%) patients: p<0.05; odds 
ratio (OR) 0.20; exact 95% confi dence 
interval (CI) 0.029–1.24. Second, sur-
veillance was conducted for only 4 
months, which did not allow for dem-
onstration of a true representative pat-
tern of strain distribution over time. 
The sequential changing predomi-
nance of rotavirus serotypes occurring 
over time has been well documented 
for many years (2).
The authors stated that the “vac-
cine does not afford complete protec-
tion against infection” (1). For those 
not paying close attention to data 
analysis, this statement could be mis-
interpreted to mean that the vaccine 
may not protect against P[4]G2. To the 
contrary, even with a small sample size 
and low vaccine coverage, additional 
analyses of the original data show that 
the live, oral, attenuated human rota-
virus vaccine can protect against the 
100% predominance of P[4]G2.
In a large phase III trial conducted in 
Latin America and Finland, a nonsig-
nifi cant but protective trend was ob-
served against severe disease associ-
ated with P[4]G2 (3). Furthermore, in 
a subsequent meta-analysis, protection 
against P[4]G2 rotavirus gastroenteri-
tis of any severity was 81% (95% CI 
31–96) and protection against severe 
rotavirus gastroenteritis was 71% 
(95% CI 20–91) (4). 
To reinforce the hypothesis that 
predominance of P[4]G2 strains in 
Aracaju is unrelated to vaccine use, it 
is worth mentioning that P[4]G2 rota-
viruses appear to display an ≈10-year 
cyclic pattern of occurrence in Brazil 
(5). Although the data presented in 
the original article may cause misin-
terpretation about vaccine protection, 
the article highlights the need for 
well-designed postmarketing stud-
ies to assess both vaccine impact and 
strain surveillance, in compliance with 
recent World Health Organization rec-
ommendations (6).
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In Response: We acknowledge 
the comments by Patel et al. (1) and 
by Linhares and Velázquez (2) about 
our article that documented the pres-
ence of a single rotavirus genotype 
(P[4]G2) in Aracaju, northeastern Bra-
zil, after the introduction of a human, 
monovalent rotavirus vaccine (3). 
Both letters emphasize that the pre-
dominance of P[4]G2 may be caused 
by a natural genotype variation un-
related to vaccination. We agree that 
our observation could be explained by 
natural variation of circulating rota-
virus genotypes in the region, but an 
alternative possibility is that the intro-
duction of the G1P[8] rotavirus vac-
cine into the childhood immunization 
schedule created conditions in which 
P[4]G2 strains had a selective advan-
tage over strains with which the vac-
cine shares G type, P type, or both.
According to a systematic review 
of rotavirus genotypes reported in the 
25 years preceding introduction of 
the vaccine in Brazil, the prevalence 
of P[4]G2 strains varied from 19% 
(1986–1995) to 12% (1996–2000) to 
1% thereafter, thus not reaching the 
detection rate we observed in Aracaju 
(R.Q. Gurgel et al., unpub data). Fur-
thermore, in the ensuing 8-month peri-
od, no genotype other than P[4]G2 had 
been detected in Aracaju, suggesting 
that our initial fi ndings were not spuri-
ous (R.Q. Gurgel et al., unpub data). In 
addition, in a separate study we con-
ducted in Recife, a city 500 km north 
of Aracaju, we observed a signifi cant 
increase in the proportion of G2 strains 
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